Vaccine Plasma for the Treatment of COVID-19 Infectio

Not Applicable

• Conditions: COVID-19; SARS-CoV-2; C01.748.214

• Registration Number: RBR-2ggx7sm
• Lead Sponsor: Ministério da Ciência, Tecnologia e Inovações

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-11
• Study Completion: 2023-03-30
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Age = 18 years with or without comorbidity; COVID-19 mild (WHO clinical progression scale = 2); Symptoms duration less than 72 hours; Laboratory confirmation of COVID-19, by detecting the viral antigen in respiratory secretions, collected by nasal swab (PanbioTM COVID-19 Ag, Abbott®); Signature, by the patient or a legal representative, of the informed consent form

Exclusion Criteria

Pregnant women; Patients in palliative care; Refusal to sign the TCLEP; Patients immunized with two doses of the immunizers, with the exception of individuals over 80 years of age who have been immunized with Coronavac vaccine for more than 6 months; Patients with suspected reinfection; Allergic reactions prior to plasma transfusion

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of patients requiring hospitalization for complications of SARS-CoV-2 infection on day 28. Measured by monitoring the participant's medical record in case of hospital admission and compared to the control group (no treatment)